Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or antagonist.
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A bioink for cryobioprinting is described. The bioink comprises a decellularized extracellular matrix (dECM)-based hydrogel and a saccharide cryoprotectant. A method of making a 3D-printed biomaterial is also described, which includes depositing a bioink comprising a dECM-based hydrogel, cells, and a saccharide cryoprotectant from a 3D printer onto a freezing plate to form a frozen bioink filament; depositing additional bioink from a 3D printer in contact with a previously placed frozen bioink filament to form a 3D-printed biomaterial comprising a plurality of frozen bioink filaments; and removing the 3D-printed biomaterial from the freezing plate. 3D-printed biomaterials made according to the method are also described.
Smart needle systems and related methods, such as smart injection needle system for accurate characterization of cell types, concentrations, and viability, are generally provided. In some embodiments, fluidic components (e.g., configured to interface with a medical device such as a syringe or in-line flow system) are provided.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
4.
COMPOSITIONS, SYSTEMS AND METHODS RELATING TO THE IDENTIFICATION OF HLA CLASS II-BINDING PEPTIDES
The technology described herein is directed to compositions and methods for generating synthetic antigen presenting cells (APCs) that express a single HLA-II allotype and key genes for HLA-II processing and presentation, and express no other HLA-II allele. Further disclosed are systems and methods of using the synthetic APCs for identifying allele-specific HLA Class II (HLA-II) peptides using genetic screening.
The disclosure provides compositions and methods for treating inflammatory bowel disease (IBD) by inhibiting signaling molecules of the IL1 signaling pathway. Specifically, methods for treating IBD are provided, the methods comprising administering to subjects having IBD inhibitors of IL1 receptor 1 (IL1R1), inhibitors of transcription factors MEOX1 and MAFF to block MEOX1 and MAFF signaling in intestinal stroma cells.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
6.
LUMINESCENCE CASCADE SENSOR FOR POINT-OF-CARE PATHOGEN DETECTION
22, yielding oxyluciferin and luminescence. Repeated catalytic cycles increase a measurable signal of the luminescence. An optical sensor can capture an image of the luminescence and the presence of tagged target components can be determined based on an amount of luminescence in the image.
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
Stabilized forms of Gal-1, and a method of treating infection by S. pneumoniae in a subject, comprising administering a therapeutically effective amount of a Gal-1 polypeptide or modified Gal-1 polypeptide to the subject, are described.
Methods of assessing a biological sample, a system, a kit, and a computer readable storage media are provided herewith. Some of the methods include determining, in the biological sample, a concentration for protein biomarkers; analyzing the concentrations of the at biomarkers using a trained biomarker model that has been trained to discriminate between cancer samples and benign samples; and providing the model output for the assessment of a cancer. Some of the methods include assisting in the diagnosis of a breast cancer.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
The present disclosure describes microneedle array compositions comprising a plurality of microneedles projecting from a substrate. Each microneedle of the plurality of microneedles comprises a penetrating tip and a base that is integrally connected with the substrate, wherein each microneedle of the plurality of microneedles is a porous microneedle composed of a degradable hyaluronic acid polymer comprising a disulfide bond coupled to a terminal amine group. Each microneedle of the plurality of microneedles comprises one or more lipid nanoparticles comprising: an amount of an ionizable lipid, an amount of a neutral lipid, an amount of cholesterol, an amount of one or more polyethylene glycol lipids (PEG-lipids), and an amount of a N-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium (DOTAP) molecule.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61M 5/162 - Needle sets, i.e. connections by puncture between reservoir and tube
Systems and methods related to drug delivery are provided. In one arrangement, a fluid is administered to a subject in drinkable form, which can partially or fully solidify in the stomach or another area of the gastrointestinal tract to form a drug release article or composition.
Described herein are high-throughput platforms and methods of using the platforms that enable the identification of cellular and molecular interactions in high-throughput screens.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
13.
SYSTEM AND METHOD FOR QUANTITATIVE PATHOLOGY USING MASS SPECTROMETRY IMAGING
An apparatus for facilitating quantitative anatomic pathology using mass spectrometry imaging includes a solid support having at least one flat surface, a tissue homogenate having a thickness mounted to the at least one flat surface of the solid support, and a quantitative array having a thickness and comprising a tissue microarray having a plurality of wells and a series of varying concentrations of an isotopically labeled metabolite deposited in the plurality of wells. The quantitative array is mounted over the tissue homogenate on the solid support.
An organ-on-a-chip (OoC) platform can link one or more OoC modules in parallel, mimicking oxygen levels of cultures with biological materials housed therein in each OoC module. Each OoC module can include an oxygen sensor; an oxygen scavenger to decrease an oxygen level within the culture medium surrounding the at least one type of biological material. Each OoC module can be connected to a controller, the controller comprising: a memory storing instructions; and a processor configured to access the memory to execute the instructions to at least: for each of the at least one OoC module, ensure that the oxygen level of the culture medium surrounding the at least one type of biological material is physiological based on control of the oxygen scavenger.
Method and system for generating predicted trajectories for navigating a catheter through a lumen, the system including: a steerable catheter including a proximal end, a distal end, a catheter tip, and a tool channel extending from the proximal end to the distal end; an imaging device disposed within the steerable catheter; a console including a system controller, a display controller, and a display; and a navigation module configured to: receive preoperative data and multiple consecutive images from the imaging device from the system controller, and output information based on the received preoperative data and the multiple consecutive images, the information including at least one of: a location, a direction, or a recommended trajectory for navigating the catheter through the lumen.
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
The present disclosure relates to generally to methods of ameliorating or treating the neurological effects of microglial activation and methods of ameliorating or treating specific diseases that affect the central nervous system (CNS) by administering an anti-CD3 antibody in combination with a GLP-1 agonist.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
In accordance with an aspect of the present disclosure, a tissue extraction device may include a bag having an interior and a plurality of cutting elements extending through the interior of the bag.
A61B 17/221 - Calculus gripping devices in the form of loops or baskets
A61B 10/02 - Instruments for taking cell samples or for biopsy
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
19.
BRANCHED POLY(-AMINO ESTERS) FOR THE DELIVERY OF NUCLEIC ACIDS
The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease.
The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease.
System configured to facilitate locomotion at a location internal to a subject are generally presented. In some embodiments, the present invention generally relates to enteroscopic robots and related methods, such as bioinspired soft enteroscopic robots for facilitating locomotion, steering, and intervention in the small intestine. In some embodiments, the system comprises a flexible linear actuator, a first expandable actuator operably linked to the first end of the flexible linear actuator, and a second expandable actuator operably linked to the second end of the flexible linear actuator. In some embodiments, the system enables the delivery of one or more tools, one or more pharmaceutical agents, and/or one or more electronic components to a location internal to the subject (e.g., the small intestine).
The present disclosure provides, inter alia, compositions and methods for detecting changes in level of expression of cell-surface Type 2 terminal lactosamines on a population of cultured cells propagated under different conditions. The disclosure also provides compositions and methods for enforcing stably expressed glycans on human cells. In certain embodiments, the compositions and/or methods utilize one or more members of the α(1,3)-fucosyltransferase family. In certain embodiments, glycoengineered CD44 glycosylated product (e.g. HCELL) is stable for at least 48 hours at 4° C., with retained expression after cell cryopreservation.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
22.
TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE
The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. Disclosed are novel gene dependencies in the pathogenic immune cell state. Also, disclosed are methods for modifying immune cells characterized by the pathogenic immune cell state.
Described herein are multiplex single molecule assays for ultrasensitive detection of biomolecules, based on an ultrasensitive multiplex digital ELISA platform that substantially reduces cross-reactivity, and methods of use thereof.
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
TARGETING THE RHOA SIGNALING PATHWAY TO CORRECT DISRUPTED RETROMER-DEPENDENT TRAFFICKING
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
25.
SYSTEM AND METHOD FOR PERCUTANEOUS DEPLOYMENT OF SENSORS
A method for tracking the location of a tissue mass comprising disposing a J-bar and electrical lead assembly within a needle cannula lumen; disposing the needle cannula within an outer cannula lumen; inserting the outer cannula into the anatomy of the patient; moving the needle cannula distally relative to the outer cannula; applying a force so that the J-bar and electrical lead assembly moves distally such that the fiducial sensor is anchored proximate to the tissue mass; moving the outer cannula and needle cannula proximally in concert, until the distal end of the outer cannula and the distal end of the needle cannula are disposed at the surface of the skin; applying a force so that the expandable basket moves distally, such that the expandable basket is disposed at the surface of the patient's skin with the electrical lead extending between the fiducial sensor and the expandable basket.
A61B 6/12 - Arrangements for detecting or locating foreign bodies
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
Described in certain exemplary embodiments herein are engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and/or nucleus of cells. In certain embodiments, an engineered Acr polypeptide comprises an Acr polypeptide operatively coupled to a cargo delivery molecule, wherein the cargo delivery molecule is capable of binding or otherwise interacting with a pore-forming polypeptide. Also described in certain exemplary embodiments are methods of Acr delivery to cells via the engineered Acr polypeptides and delivery systems of the present disclosure.
Embodiments provide computer-implemented methods, systems, and media for estimating a subject's body composition from ultrasound. Images acquired at standardized sites (e.g., biceps, abdominal wall, quadriceps) are quality-gated and preprocessed (scale, denoise, normalization). A neural network segments tissue layers; features from the image and masks feed a predictor that outputs fat mass (FM), fat-free mass (FFM), and, in some embodiments, adiposity indices (e.g., preperitoneal fat thickness, visceral-to-subcutaneous ratio). Multi-site predictions may be fused. The system can compute uncertainty, produce explanation overlays, and generate a report with values and visit-to-visit trends. An acquisition-planning module selects a minimal site subset to meet an error target. Implementations support edge/cloud inference and optional fusion with clinical covariates or laboratory data. The approach applies to neonatal, pediatric, adult, pregnant, and diabetic subjects for prenatal nutrition care, metabolic screening, and longitudinal monitoring.
The disclosure provides methods to facilitate the diagnosis of prostate cancer. In particular, the methods disclosed herein can be used to distinguish prostate cancer from benign prostatic hyperplasia. The methods comprise determining in a sample of the subject a level of one or more biomarkers selected from the group consisting of: mucin 3 (MUC3); pepsinogen 3 preproprotein (PGA3); β-2-microglobulin (β2M); PIK3IP1; uromodulin; prion protein; apolipoprotein D; WAP four-disulfide core domain protein 2; kininogen 1 variant; collagen alpha-1(III) chain; osteopontin-c (OPN-c); epidermal growth factor (beta-urogastrone); unnamed protein product (GI 158261423); cadherin-13 isoform 1 preproprotein; collagen alpha 1 chain precursor variant; ankyrin repeat domain-containing protein 11; pro-alpha 2(I) collagen; sulfatase 2 isoform b precursor; MASP-2 protein; Inositol 1,4,5-triphosphate receptor, type 2, isoform CRA_b; unnamed protein product (GI 47077082); alpha-1-acid glycoprotein 1 precursor; Zinc-alpha-2-glycoprotein precursor (ZAG); HSCARG protein, isoform CRA_b; alpha2-HS glycoprotein; and SNC66 protein, and correlating the level of the one or more biomarkers to a reference level to facilitate diagnosis of prostate cancer or BPH.
Disclosed herein are methods for of preventing a human immunodeficiency virus (HIV) infection in a subject or treating a subject suffering from an infectious disease caused by HIV, comprising administering to the subject an effective amount of a killer cell lectin-like receptor G1 (KLRG1) antagonist. The methods can further comprise administering other therapies to the subject, such as an anti-viral therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Compositions and methods for detecting bacterial pathogens containing microbial resistance genes in a sample, as well as methods for selecting a treatment for human infections involving such organisms. The methods involve carrying out a series of reactions in parallel where each reaction involves detecting a bacterial species or resistance gene in a sample using a CRISPR-Cas13a reaction. In some embodiments, the methods involve culturing a blood sample to increase the concentration of bacteria in the sample and/or direct detection of bacterial pathogens and/or microbial resistance genes in a blood sample.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
31.
ARTICLES FOR UNDERWATER ADHESION FOR SOFT SUBSTRATES
Embodiments described herein generally relate to bio-inspired articles for underwater adhesion for soft substrates and related methods. In some embodiments, an article configured for underwater adhesion to soft substrates is provided. In some embodiments, the article comprises: an adhesive disk, comprising: an elastomeric compartment; and a plurality of tilt-angled lamellae structures, wherein each adhesive compartment is configured to separately seal lamellae pairs for hydrostatic differentiation. In some embodiments, the article further comprises a backbone support structure. In some embodiments, the article further comprises a pharmaceutical agent (e.g., drug delivery polymer matrix, microneedles), electronic component (e.g., RFID), and/or biochemical sensor (e.g., impedance sensor) associated with the disk. In some embodiments, the tilt-angled lamellae have an angle of greater than or equal to 0 degrees and less than or equal to 60 degrees. In some embodiments, the underwater adhesion of the article does not require the external application of vacuum pressure.
The technology described herein is directed to devices and methods for automated chromatography analysis of multiple samples in parallel. The devices include a pump, a computing device, and a stand having an upper portion including columns containing a resin and a bottom portion including wells or tubes. The invention also provides disclosures for chromatography columns and methods for purification of extracellular vesicles from a biological sample.
C12N 5/078 - Cells from blood or from the immune system
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
B01D 15/34 - Size-selective separation, e.g. size-exclusion chromatographyGel filtrationPermeation
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
33.
ELECTRICALLY-TRIGGERED MICROACTUATOR POWERED BY ALUMINIUM-NICKEL NANOFILM
The disclosure relates, in various embodiments, to devices, articles, and methods for jetting an active pharmaceutical ingredient into a patient using an electrically-triggered microactuator powered by a reactive material such as an aluminium-nickel nanofilm.
The present disclosure relates, in various aspects, to devices comprising biodegradable (e.g., bioresorbable) RFID antennas and dissolvable coatings. By employing fully biodegradable materials, the devices provided herein may obviate the need for device retrieval or battery replacement, thereby mitigating electronic waste. Moreover, the tags were compatible with standard gelatin or hydroxypropyl methylcellulose (HPMC) capsules, further enhancing clinical translational potential.
SYSTEMS AND METHODS FOR REAL TIME, QUANTITATIVE, HYPERSPECTRAL AND OPTICAL PROPERTY IMAGING FOR IN VIVO INTRAOPERATIVE MULTIPLEX MOLECULAR GUIDED SURGERY
Board of Regents, The University of Texas System (USA)
William Marsh Rice University (USA)
The Brigham and Women’s Hospital, Inc. (USA)
Inventor
Quevedo, Pablo Valdes
Veeraraghavan, Ashok
Kotwal, Alankar
Saragadam, Vishwanath
Bernstock, Joshua D.
Abstract
A method of the present disclosure, among others, involves illuminating a tissue sample with light across both a visible wavelength range and a near-infrared wavelength range, wherein the tissue sample has been administered with at least one fluorescent agent; acquiring a snapshot image of the tissue sample, wherein pixels of the snapshot image capture different 2D views of the tissue sample at a same time along with multiple wavelengths of light incident on a respective sensor pixel; creating a hyperspectral image cube of the tissue sample from the snapshot image; performing spectrally-resolved quantitative fluorescence measurements on the hyperspectral image cube; analyzing the spectrally-resolved quantitative fluorescence measurements to detect a presence of at least one fluorescent agent in the tissue sample; and/or identifying an optical fingerprint of an abnormal region of the tissue sample based on the detected at least one fluorescent agent in the tissue sample.
A method includes receiving MR data for a subject, generating a map of atrophy coordinates for the subject using a set of volumetric MR data from the MR data, defining a plurality of regions of interest (ROIs) for the subject based on the atrophy coordinates in the map of atrophy coordinates, generating a connectivity map for each ROI using a set of functional connectivity data from the MR data, retrieving a unified schizophrenia network connectivity map of atrophy patterns, determining a probability of progression to schizophrenia for the subject based on the connectivity map for each ROI and the unified schizophrenia network connectivity map of atrophy patterns, and generating a report including at least the probability of progression to schizophrenia for the subject. The method can further include identifying target(s) for a proactive intervention for the subject based on the connectivity maps for each ROI.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
37.
COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA
In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.
Systems and methods are provided for a method is provided for ranking a cohort of reproductive cellular structures. A set of images, each representing a reproductive cellular structure of the cohort of reproductive cellular structures, is provided to a predictive model utilizing an attention mechanism to provide an output representing a likelihood of a successful outcome associated with the cohort of reproductive cellular structures. The predictive model is trained using multiple instance learning on a set of training samples, with each training sample including a set of images representing a set of reproductive cellular structures and a value representing an outcome associated with the set of reproductive cellular structures. A total attention associated with each of the set of images at the predictive model is determined. The cohort of reproductive cellular structures is ranked according to the total attention associated with each of the set of images.
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
39.
TRANSCRIPTOMIC CLOCKS OF BIOLOGICAL AGE AND LIFESPAN
Provided herein are methods that use gene transcription levels to quantify mammalian expected total lifespan, remaining lifespan, chronological age and lifespan-adjusted biological age and predict whether an intervention will be protective or damaging to lifespan and health outcomes.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
40.
OLIGOMER-INDUCED RECONSTITUTION OF BIOLUMINESCENCE SENSORS FOR MULTIPLEX DETECTION OF ANALYTES
Described herein are fusion proteins and methods of using those fusion proteins for the detection and identification of analytes (e.g., multimeric proteins expressed by pathogenic organisms or mammalian cells). In some embodiments, it includes a plurality of pairs of fusion proteins distinct for one analyte wherein each pair comprises i) a first fusion protein comprising one or more binding domains fused to a first portion of a reporter protein, and ii) a second fusion protein comprising one or more binding domains fused to a second portion of the same reporter protein, wherein the first and second portions of the reporter protein, when together, comprise the reporter protein in its entirety and restore its function, wherein the first fusion protein and/or the second fusion protein further comprises a fluorophore, and wherein the fluorophore for each pair has a distinguishable emission spectrum.
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
42.
COMPOSITIONS AND METHODS FOR TREHALOSE PHOSPHOLIPIDS
Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.
A bioink formulation for digital light processing bioprinting comprising a mixture of a biocompatible cleavable polymer precursor, a biocompatible non-cleavable polymer precursor, and a photoinitiator is described. Three-dimensional (3D) objects prepared using these bioink formulations are also described. In addition, a method of 3D bioprinting is described. The method includes providing a bioink formulation in a 3D bioprinter vat; repeatedly photoactivating the biocompatible photoactive polymer precursors in the 3D bioprinter vat on a build plate immersed in the vat to form a 3D bioprinted object comprising polymers having a series of predefined shapes across the vertical direction based on a set of sliced images; and treating the 3D bioprinted object with an agent that cleaves chemical bonds within the cleavable polymer.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
B33Y 40/20 - Post-treatment, e.g. curing, coating or polishing
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
B33Y 80/00 - Products made by additive manufacturing
C08F 291/12 - Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds according to more than one of the groups on to nitrogen-containing macromolecules
C09D 4/06 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond in combination with a macromolecular compound other than an unsaturated polymer of groups
C09D 151/08 - Coating compositions based on graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCoating compositions based on derivatives of such polymers grafted on to macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
45.
AUTOMATED EVALUATION OF QUALITY ASSURANCE METRICS FOR ASSISTED REPRODUCTION PROCEDURES
Systems and methods are provided for assigning a quality parameter to a reproductive cellular structure. An image of the reproductive cellular structure is obtained. The image of the reproductive cellular structure is provided to a neural network to generate a value representing a morphology of the reproductive cellular structure. The value is compared to a predefined standard to provide a quality assurance metric representing one of a medical personnel, a facility, a growth medium, and an identity of the reproductive cellular structure.
Discussed herein are novel engineered polypeptides which are effective at cutting and tagging H3 histone tails from endogenous histones, facilitating multiplex "cut-and-paste" middle down proteomics with tandem mass tags. This cut-and-paste proteomics approach permits the quantitative analysis of H3 histone modification crosstalk after treatment with different histone deacetylase inhibitors.
The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.
Provided herein are methods that use methylation of causal CpG sites to quantify aging and predict whether an intervention will be protective or damaging to the aging process.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and/or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The invention features a mucosal coating composition including: (i) water: (ii) at least one mucoadhesive polymer/polysaccharide (e.g., a concentration between 0.1-20% w/v); and (iii) at least one surfactant (e.g., a concentration between 0.005-5% w/v). Exhibit long-lasting residence times on mucosal tissues and prophylactic protection against transmucosal pathogens.
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
Compositions comprising peptides that bind specifically to BΔg (deglycosylated brevican), and methods of use thereof to deliver therapeutic and diagnostic agents to brevican-expressing cells, e.g., cancerous cells, e.g., brain cancer cells, e.g., glioblastoma cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Compositions comprising memory T cell Targeting Constructs comprising an anti-T cell antibody or antigen-binding portion thereof linked to a near-infrared photoactivated cytotoxin, e.g., a photoactive adduct of an infrared dye, and methods of use thereof for reducing numbers of pathogenic T cells selectively in peripheral tissues e.g., for treating inflammatory and autoimmune diseases.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The technology described herein is directed to devices, systems, kits, and methods relating to detecting the contents and characteristics of a fluid in a medical drain.
A61M 27/00 - Drainage appliances for wounds, or the like
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
Tissue oxygenation compositions comprising a hydrogel and an oxygen carrier compound are described. Tissue oxygenation precursor compositions and methods of using tissue oxygenation compositions for tissue oxygenation are also described.
Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.
Systems and methods are provided for decision support in toxicology assessment. The system includes a processor and a non-transitory computer readable medium storing instructions executable by the processor to provide an imager interface that receives an image of organ tissue of an animal and a vision encoder trained on a plurality of training images that receives the image of organ tissue and provides a representation of the image of organ tissue. Each training image includes an image of organ tissue of an animal. A toxicology front end generates one of a value representing lesions within the image of organ tissue or an image having a similar representation from the representation of the image of organ tissue.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61P 37/00 - Drugs for immunological or allergic disorders
Systems and methods for simulating a CBCT scan implement or include receiving a set of initial CBCT scan parameters; generating a mono-energetic simulation of the CBCT scan using the initial CBCT scan parameters; storing a slice of the mono-energetic simulation in memory; receiving a set of updated CBCT scan parameters; and modifying the stored slice of the mono-energetic simulation based on the updated CBCT scan parameters.
in silicoin silico protein evolution, surpassing current state-of-the-art methods and yielding proteins with more than 100-fold improvement of desired properties. EVOLVE-Pro demonstrates the necessity for protein engineering models to zoom in on desired functional properties rather than predicted fitness, paving the way for broader applications of AI-guided protein engineering in biology and medicine.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are compositions, kits, and methods for chromatin accessibility measurement using genome editing by double-stranded DNA cytosine deaminases (Ddds).
In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is directed to antibodies that interact with DLL4 and inhibit it from binding to NOTCH receptors. The invention also includes nucleic acids encoding the antibodies and methods of using the antibodies in research and in the prevention or treatment of various diseases and conditions.
Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.
Formulations for stabilizing Lactobacillus and Bifidobacterium strains are provided, comprising one or more excipient selected from the group consisting of D-(-)-fructose, Bacto Tryptic Soy Broth (BTSB), potassium gluconate, magnesium D-gluconate, sucrose, and/or maltodextrin, and preferably also comprising L-histidine, as are lyophilized cell populations generated using the formulations, and the use of such lyophilized cell populations.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Marassi, Francesca M.
Schifferli, Dieter M.
Waldor, Matthew Kaden
Dehinwal, Ruchika
Abstract
Salmonella entericaSalmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Various examples include microfluidic devices or a microphysiological analysis platform (MAP) device. One example MAP device includes a set of arrays. An array of the set of arrays includes a set of chambers configured to contain a set of three-dimensional (3D) tissues. A chamber of the set of chambers is configured to contain a 3D tissue of the set of 3D tissues. The array also includes a perfusion system configured to exchange fluid with the set of chambers. The perfusion system facilitates uniform development of the set of 3D tissues. The array additionally includes a set of electrodes. A subset of the set of electrodes is configured to perform non-contact monitoring of electrophysiological signals in the organoid. The example MAP device also includes a flow control component configured to control the flow of fluid through the perfusion system.
Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer and infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Provided herein are materials and methods for determining responsiveness of any therapy that enhances regulatory T cell (Treg) function in the treatment of inflammatory bowel disease (IBD). The materials and methods provided herein may be used to determine low dose IL- 2 responsiveness in a subject having an inflammatory bowel disease. The materials and methods can be used to determine low dose IL- 2 responsiveness in a blood sample prior to administering a low dose IL-2 therapy.
G01N 33/554 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 37/00 - Drugs for immunological or allergic disorders
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/6816 - Hybridisation assays characterised by the detection means
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
71.
Augmenting Mitochondria in Immune Cells for Improved Cancer Immunotherapy
LEIBNIZ-INSTITUT FÜR IMMUNTHERAPIE (LIT) (Germany)
The Brigham and Women's Hospital Inc. (USA)
Inventor
Gattinoni, Luca
Baldwin, Jeremy
Fioravanti, Jessica
Sengupta, Shiladitya
Saha, Tanmoy
Abstract
The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in mitochondrial transfer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
72.
DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION
Disclosed are sustained biodegradable implant (a depot) that releases high drug doses directly into the tumor for treating cancer. The depot comprises a biodegradable polymer and a STING agonist and/or a PARP inhibitor (PARPi); wherein the STING agonist or the PARPi is distributed in the biodegradable polymer. The depot activates anticancer innate and adaptive immunity within the tumor microenvironment and promote immune infiltration of secondary, metastatic sites.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 35/04 - Antineoplastic agents specific for metastasis
73.
RECOMBINANT HERPES SIMPLEX VIRUS-2 EXPRESSING GLYCOPROTEIN D AND B ANTIGENS
Provided herein are recombinant Herpes Simplex Virus-2 comprising sequences encoding glycoprotein D and B antigens, with two sequences encoding dominant negative UL9 proteins, compositions comprising the same, and methods of use thereof.
Self-actuating articles including, for example, self-actuating needles and/or self-actuating biopsy punches, are generally provided. Advantageously, the self-actuating articles described herein may be useful as a general platform for delivery of a wide variety of pharmaceutical drugs that are typically delivered via injection directly into tissue due to degradation in the GI tract. The self-actuating articles described herein may also be used to deliver sensors and/or take biopsies without the need for an endoscopy. In some embodiments, the article comprises a spring (e.g., a coil spring, a beam, a material having particular mechanical recovery characteristics). Those of ordinary skill in the art would understand that the term spring is not intended to be limited to coil springs, but generally encompass any reversibly compressive material and/or component which, after releasing an applied compressive force on the material/component, the material/component substantially returns to an uncompressed length of the material/component (e.g., the within 95% of the length of the material/component prior to compression).
Described in certain example embodiments herein are engineered Anti-CRISPR (Acr) polypeptides having an Acr polypeptide and one or more cell -penetrating peptides (CPPs) operatively coupled to the Acr polypeptide. Also described in several example embodiments herein are methods of producing and purifying Acr polypeptides and delivering engineered Acr polypeptides to a cell or cell population.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided herein are methods and compositions comprising pharmacological inhibitors of HIF hydroxylases (e.g., or more inhibitors of Prolyl Hydroxylase Domain enzymes (PHDs) or Factor Inhibiting HIF (FIH)) for enhancing cyanide resistance in living organisms.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61P 43/00 - Drugs for specific purposes, not provided for in groups
77.
SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES
G01N 15/02 - Investigating particle size or size distribution
G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
G01N 27/60 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrostatic variables
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
78.
SYSTEMS, METHODS, AND COMPOSITIONS FOR TREATING VASCULAR DISEASE
The Board of Trustees of the Leland Stanford Junior University (USA)
The Brigham and Women's Hospital, Inc. (USA)
Inventor
Schnitzler, Gavin Reinhardt
Engreitz, Jesse Michael
Kang, Helen Yihua
Ma, Xueyan Rosa
Gupta, Rajat Mohan
Abstract
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vascular disease in a subject involving administering a therapy to disrupt the cerebral cavernous malformation (CCM) signaling pathway in endothelial cells (e.g., arterial endothelial cells) in the subject. Also provided are methods of determining the likelihood that a subject will respond to a therapy for a vascular disease such as CAD, based on the identification of one or more loss-of-function variants in a CCM pathway associated gene in the subject.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
79.
COMPOSITIONS AND METHODS FOR DONOR-SPECIFIC ANTIBODY SCREENING AND TISSUE TYPING
in vivoin vivo zebrafish models and screening methods disclosed facilitate the study and discovery of therapeutic compounds to treat sodium channel-related cardiac diseases, e.g., by increasing sodium channel function at the membrane.
While primary lymphedema is rare, numerous cancer patients develop secondary lymphedema, or the retention of lymphatic fluid. Lymphedema is characterized by progressive, irreversible fibroadipose tissue deposition. Non-surgical approaches such as compression therapy are the most common strategies to address lymphedema but are inadequate in the long term. Surgical procedures can reconstitute lymphatic drainage, but this approach is not curative. A new approach is needed to mitigate fibroadipose tissue deposition in lymphedema.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
Described herein are chimeric antigen receptors (CARs) comprising an extracellular domain comprising a portion of an anti-triggering receptor expressed on myeloid cells 2 (TREM2) scFv for targeting macrophages expressing TREM2. Methods for producing and utilizing cells comprising the CAR are further provided herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 39/00 - Medicinal preparations containing antigens or antibodies
83.
SYSTEM AND METHOD FOR LINKING PATIENT LEVEL MOLECULAR DATA TO TREATMENT SELECTION
Pulmonary arterial hypertension (PAH) exhibits an obliterative vasculopathy where complex, integrated pathobiological signaling pathways drive vascular remodeling. In PAH, the arteriopathy includes numerous endophenotypes that occur to differing extents across patients. Variability in the proteomic and genetic profile is observed, causing phenotypic heterogeneity and inconsistent clinical responses to drug therapies. We have used network medicine to discover modifiable therapeutic targets in PAH by generating patient-specific protein-protein interaction (PPI) networks to unmask molecular interactions that identify and distinguish groups of individual patients with the same clinical phenotype. This allows personalized clinical phenotyping in PAH in those patient groups. The findings here also clarify the relationship between PAH genetic risk and pathobiology on an individual patient level, and inform treatment rationales and personalized drug selection using the PPI networks. Overall, findings from this project will advance precision medicine in PAH with direct relevance to the clinical management of patients.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
The present invention provides a method to identify and use compounds for the inhibition of abnormal or dysregulated hepatic glucose production that results in elevated blood glucose levels and associated metabolic disorders. The invention is based on the surprising discovery that the glucagon forms an obligate binding complex with aP2, which is necessary for activation of the glucagon G-coupled protein receptor.
Determining a patient-level clinical endpoint prediction based on analysis of a three-dimensional volumetric image is discussed. One example method includes generating a set of patches from a volumetric image of a tissue sample. The method also includes employing a pretrained feature encoder to extract a set of features from the set of patches. The method additionally includes generating a volume-level feature associated with the volumetric image via an aggregation based on the set of features. The method further includes generating a clinical endpoint prediction based on the volume-level feature.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
86.
METHOD OF DELIVERY OF FUSOGENIC ONCOLYTIC VIRUS AND THERAPEUTIC MOLECULES
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a method for treating cancer comprising administering to a subject in need thereof a checkpoint inhibitor in combination with a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the methods described herein is suitable for treatment of solid tumors, as well as other cancers.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
87.
COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
Described herein are compositions and methods for treating a disease in a subject by administering delivery vectors that express artificial microRNAs, artificial microRNA clusters, and/or a combination of microRNA clusters and associated non-coding RNAs to the subject. Also described herein are methods for preparing artificial microRNAs and artificial microRNA clusters.
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/078 - Cells from blood or from the immune system
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
90.
AUTOMATED EVALUATION OF QUALITY ASSURANCE METRICS FOR ASSISTED REPRODUCTION PROCEDURES
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
Provided herein are compositions and methods using a therapeutic agent targeting mTORCI and a therapeutic agent targeting MDK for treating a Tuberous Sclerosis Complex (TSC)-associated disease, e.g., Angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), or for treating sporadic LAM/AML. Also provided are methods of identifying subjects for treatment, e.g., with checkpoint inhibitors.
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for activating immune cells, for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Embodiments disclosed herein provide compositions for increasing CCL3 and/or CCL4 interactions with CCR5 and/or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocytes/macrophages that change during tumor progression from small to medium to large tumors. The ligands CCL3 and CCL4 are expressed in a specific subset of T cells (CD8+ PD-1+ TIM3+ T cells). The receptors CCR5 and CCR1 are expressed in inflammatory monocytes/macrophages. Modulation or maintenance of these interactions can allow enhanced immune responses for treating cancer, as well as for vaccination.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
94.
SYSTEMS, DEVICES, AND METHODS FOR GENERATING MACHINE LEARNING MODELS AND USING THE MACHINE LEARNING MODELS FOR EARLY PREDICTION AND PREVENTION OF PREECLAMPSIA
Disclosed herein are methods and systems for determining risk of preeclampsia. The system can include (a) a computer comprising: (i) a processor; and (II) a memory, coupled to the processor, the memory storing a module comprising: (1) test data for a sample from a subject including values indicating a quantitative measure of one or more markers; (2) a classification rule which, based on values including the measurements, classifies the subject as being at risk of preeclampsia, wherein the classification rule is configured to have a sensitivity of at least 75%, at least 85% or at least 95%; and (3) computer executable instructions for implementing the classification rule on the test data.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
95.
COMPOSITIONS AND METHODS FOR TREATING CHRONIC ALLOGRAFT REJECTION
The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.
This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas. The disclosure also relates to shear-thinning compositions comprising silicate nanoparticles, gelatin or a derivative thereof, and a contrast agent. In some examples, the shear-thinning compositions comprise about 1.5% to about 10% by weight of silicate nanoparticles and about 0.5% to about 6.75% by weight of gelatin or a derivative thereof.
The present disclosure provides include kits, compositions, and methods related to impaired respiratory health (e.g., diseases and conditions relating to lung injury). In particular, the present disclosure provides include kits, compositions, and methods for quantifying protein biomarkers associated with impaired respiratory health and assessing the risk of, monitoring, treating and/or preventing, interstitial lung diseases (ILDs).
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
99.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (IL-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
100.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (1L-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
